Italia markets closed

Dow Jones
39.872,99
+66,22(+0,17%)
Nasdaq
16.832,62
+37,75(+0,22%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0859
-0,0002(-0,02%)
Bitcoin EUR
64.167,61
+359,98(+0,56%)
CMC Crypto 200
1.515,10
+26,56(+1,78%)

NVCR Jan 2026 7.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,2000

0,0000

(0,00%)

In data: 03:15PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in